Karyopharm Awaits Key Myelofibrosis Data as Revenue Stagnates

Event summary

  • Karyopharm reports $146M total revenue for 2025, with U.S. XPOVIO net product revenue at $115M.
  • Phase 3 SENTRY trial in myelofibrosis expected to report top-line data in March 2026.
  • Phase 3 XPORT-EC-042 trial in endometrial cancer on track for mid-2026 readout.
  • 2026 revenue guidance set at $130M–$150M, with U.S. XPOVIO revenue projected at $115M–$130M.
  • Cash position declined to $64.1M by year-end 2025 from $109.1M in 2024.

The big picture

Karyopharm is at a critical juncture, with near-term catalysts in myelofibrosis and endometrial cancer trials. The company's ability to leverage these potential successes will be key to offsetting stagnant XPOVIO revenues and improving its financial footing. The biotech sector's focus on targeted cancer therapies underscores the strategic importance of these upcoming data readouts.

What we're watching

Clinical Trial Outcomes
Whether the Phase 3 SENTRY trial in myelofibrosis delivers positive top-line data in March 2026, which could expand Karyopharm's therapeutic portfolio.
Revenue Growth
How Karyopharm will sustain or grow XPOVIO revenues in a competitive multiple myeloma market.
Financial Sustainability
The pace at which Karyopharm can extend its cash runway beyond the second quarter of 2026.

Related topics

Oncology